Cloudbreak Pharma (HKG:2592) unit ADS Therapeutics submitted an investigational new drug application for CBT-199 to the U.S. Food and Drug Administration (FDA), a Monday Hong Kong bourse filing said.
CBT-199 is a novel topical ophthalmic emulsion indicated for the treatment of presbyopia, a gradual loss of the eyes' ability to focus on nearby objects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments